Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 99.08M P/E - EPS this Y 39.30% Ern Qtrly Grth -
Income -276.06M Forward P/E -0.76 EPS next Y 19.30% 50D Avg Chg -9.00%
Sales 90.12M PEG 0.23 EPS past 5Y - 200D Avg Chg -70.00%
Dividend N/A Price/Book 0.41 EPS next 5Y -7.30% 52W High Chg -90.00%
Recommedations 3.20 Quick Ratio 5.97 Shares Outstanding 183.62M 52W Low Chg 3.00%
Insider Own 1.10% ROA -15.25% Shares Float 163.11M Beta 0.91
Inst Own 66.76% ROE -110.95% Shares Shorted/Prior 3.11M/2.51M Price 0.52
Gross Margin 62.53% Profit Margin - Avg. Volume 3,442,837 Target Price 2.00
Oper. Margin -128.37% Earnings Date May 7 Volume 1,328,463 Change 0.58%
About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Nektar Therapeutics News
04/03/24 Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
03/22/24 Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
03/06/24 Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
03/05/24 Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
03/05/24 Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript
03/05/24 Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
03/05/24 Q4 2023 Nektar Therapeutics Earnings Call
03/04/24 Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
03/04/24 Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results
03/04/24 Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
03/04/24 Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
02/27/24 Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference
02/26/24 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets
02/20/24 Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
02/16/24 Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
01/09/24 BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
01/03/24 Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
12/30/23 Following a 75% decline over last year, recent gains may please Nektar Therapeutics (NASDAQ:NKTR) institutional owners
12/11/23 Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
12/08/23 Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?
NKTR Chatroom

User Image NSradar Posted - 1 hour ago

$NKTR where is the link for the insider buy I keep hearing about? Anyone?

User Image Doozio Posted - 4 hours ago

$NKTR PAYtience until they drop da $hook on da 🐑 n da BAND is together in 🧠⏰?

User Image NSradar Posted - 6 hours ago

$NKTR we closed at the high of the day. U know what that means boys
 $ tmrw (iA)

User Image j00bacca Posted - 8 hours ago

$NKTR to the moon folks

User Image j00bacca Posted - 10 hours ago

$NKTR gobbling up shares on sale

User Image ElectricJ Posted - 11 hours ago

$NKTR flying high, large insider buys

User Image matthew122 Posted - 13 hours ago

$NKTR

User Image NSradar Posted - 04/30/24

$NKTR who saw LLY earnings today? They got the $ to Settle or BO $NKTR

User Image BK217 Posted - 04/30/24

$NKTR my guess is we’ll be in $2s in May

User Image calbucs Posted - 04/29/24

$NKTR Another BO .

User Image calbucs Posted - 04/29/24

$NKTR let’s go to $2 then build from there . With potential BO and Lawsuit to LLY moving forward we could explode to $10 plus .

User Image johnkimble Posted - 04/29/24

$ASLN we have been building a position and stepping up the pace no issue crossing the bid/ask spread to get volume on today and will keep paying up until at least 50 cents. This stock should be $5 but AI/algo funds are shorting it since the cash runway only shows months; they fail to see this company can easily get more cash when needed and dilution vs value is quite small Tagging my friends in $NKTR here

User Image j00bacca Posted - 04/29/24

$NKTR why is this popping today?

User Image NSradar Posted - 04/26/24

$NKTR sellers are exhausted

User Image breakoutstock Posted - 04/26/24

User Image onemillion2012 Posted - 04/26/24

$NKTR

User Image toadmost Posted - 04/26/24

$NKTR

User Image johnkimble Posted - 04/26/24

$NKTR still good

User Image calbucs Posted - 04/25/24

$NKTR Good news and they drop it .10 cents . That makes perfect sense ?

User Image PercyFinn Posted - 04/25/24

$NKTR Is this a new chapter for NKTR? Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases https://www.abc27.com/business/press-releases/globenewswire/9104653/biolojic-design-announces-that-nektar-therapeutics-has-exercised-its-license-option-to-develop-an-ai-designed-agonistic-antibody-targeting-tnfr2-for-the-treatment-of-autoimmune-diseases/

User Image yayanaji Posted - 04/24/24

$NKTR I'm thinking about but some this stock for the long term. Can anyone tell me what this company does? And why drop from high $100+ to $1? Please tell me before I buy. Thanks

User Image breakoutstock Posted - 04/24/24

$NKTR all you need is this the 10x you’ve been waiting for. It’s coming.

User Image matthew122 Posted - 04/23/24

$NKTR such a good investment bought at 0.70 almost shat myself when I saw it at 0.45 a while back.

User Image breakman1010 Posted - 04/23/24

$JAGX $NKTR Might have potential.?

User Image calbucs Posted - 04/22/24

$NKTR Good Volume day , 2 mill plus . The shorts are keeping quiet on this one right now . If Volume continues we could take $2 out . Short volume below .

User Image TMak Posted - 04/22/24

$NKTR Volume dried early this session so SP upward motion collapsed. This is not a short term hold IMO. Will be a while before LLY trial and verdict happens and no real catalyst anticipated in the immediate future. Long term catalysts ahead and I think this is a long term buyout candidate here. Once pipeline develops further, big pharma is likely to swoop in and try to secure a buyout. Again, BO opportunity is not in the near term IMO. GLTA holding long term here.

User Image TalkMarkets Posted - 04/22/24

Sweet Nektar? $NKTR https://talkmarkets.com/content/stocks--equities/sweet-nektar?post=442266

User Image rabbitsoup Posted - 04/22/24

$NKTR https://www.barchart.com/stocks/quotes/NKTR/opinion

User Image breakoutstock Posted - 04/22/24

$NKTR nice way for a Monday.

User Image RallyRaider Posted - 04/22/24

$NKTR chart says 2$

Analyst Ratings
Jefferies Hold Mar 6, 24
TD Cowen Outperform Nov 9, 23
Mizuho Neutral Aug 7, 23
Jefferies Hold May 10, 23
Oppenheimer Perform Mar 6, 23
Goldman Sachs Sell Feb 27, 23
SVB Leerink Market Perform Feb 24, 23
Jefferies Underperform Feb 24, 23
JP Morgan Underweight Aug 8, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Nov 17 Sell 0.49 9,646 4,727 274,039 11/20/23
Wilson Mark Andrew Chief Legal Officer Chief Legal Officer Nov 17 Sell 0.49 7,179 3,518 243,780 11/20/23
ROBIN HOWARD W President & CEO President & CEO Nov 17 Sell 0.49 19,877 9,740 899,922 11/20/23
Curet Myriam Director Director Sep 18 Sell 0.69 4,359 3,008 27,418 09/20/23
CHESS ROBERT Director Director Sep 18 Sell 0.67 10,200 6,834 274,773 09/20/23
Ajer Jeffrey Robert Director Director Sep 18 Sell 0.69 4,359 3,008 34,153 09/20/23
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Aug 16 Sell 0.78 9,703 7,568 283,685 08/17/23
Wilson Mark Andrew Chief Legal Officer Chief Legal Officer Aug 16 Sell 0.78 7,221 5,632 250,959 08/17/23
ROBIN HOWARD W President & CEO President & CEO Aug 16 Sell 0.78 19,998 15,598 919,799 08/17/23
WHITFIELD ROY A Director Director Jun 14 Sell 0.57 30,000 17,100 216,250 06/15/23
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer May 16 Sell 0.72 9,791 7,050 293,388 05/17/23
Wilson Mark Andrew Chief Legal Officer Chief Legal Officer May 16 Sell 0.72 7,543 5,431 257,680 05/17/23
ROBIN HOWARD W President & CEO President & CEO May 16 Sell 0.72 20,361 14,660 939,797 05/17/23
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Feb 16 Sell 3.00 10,484 31,452 303,179 02/17/23
Wilson Mark Andrew Chief Legal Officer Chief Legal Officer Feb 16 Sell 3.00 8,275 24,825 265,223 02/17/23
Thomsen Jillian B. Chief Financial Offi.. Chief Financial Officer Feb 16 Sell 3.00 10,267 30,801 313,497 02/17/23
ROBIN HOWARD W President & CEO President & CEO Feb 16 Sell 3.00 19,635 58,905 960,158 02/17/23
Curet Myriam Director Director Sep 23 Sell 3.16 4,198 13,266 31,777 09/26/22
Ajer Jeffrey Robert Director Director Sep 23 Sell 3.16 4,198 13,266 38,512 09/26/22
CHESS ROBERT Director Director Sep 22 Sell 3.19 5,100 16,269 228,179 09/26/22
EASTHAM KARIN Director Director Sep 13 Sell 3.61 21,267 76,774 13,033 09/14/22
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Aug 18 Sell 4.65 73,716 342,779 327,123 08/19/22
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Aug 15 Sell 4.76 10,560 50,266 400,839 08/17/22
Wilson Mark Andrew SVP & General Counse.. SVP & General Counsel Aug 15 Sell 4.76 3,189 15,180 281,188 08/17/22
Thomsen Jillian B. SVP & Chief Accounti.. SVP & Chief Accounting Officer Aug 15 Sell 4.76 2,006 9,549 334,859 08/17/22
ROBIN HOWARD W President & CEO President & CEO Aug 15 Sell 4.76 13,759 65,493 1,017,807 08/17/22
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer May 15 Sell 3.95 21,673 85,608 276,399 05/17/22
Wilson Mark Andrew SVP & General Counse.. SVP & General Counsel May 16 Sell 3.95 3,136 12,387 117,939 05/17/22
Thomsen Jillian B. SVP & Chief Accounti.. SVP & Chief Accounting Officer May 15 Sell 3.95 5,841 23,072 170,427 05/17/22
ROBIN HOWARD W President & CEO President & CEO May 15 Sell 3.95 36,529 144,290 620,941 05/17/22
NORTHCOTT JOHN SVP & Chief Commerci.. SVP & Chief Commercial Officer May 16 Sell 3.95 4,592 18,138 223,210 05/17/22
Labrucherie Gil M SVP, COO & CFO SVP, COO & CFO May 15 Sell 3.95 17,448 68,920 312,905 05/17/22
Zalevsky Jonathan Chief R&D Officer Chief R&D Officer Feb 16 Sell 10.95 10,912 119,486 274,122 02/18/22
Wilson Mark Andrew SVP & General Counse.. SVP & General Counsel Feb 16 Sell 10.95 3,661 40,088 121,075 02/18/22
Thomsen Jillian B. SVP & Chief Accounti.. SVP & Chief Accounting Officer Feb 16 Sell 10.95 2,363 25,875 165,318 02/18/22
ROBIN HOWARD W President & CEO President & CEO Feb 16 Sell 10.95 12,480 136,656 589,020 02/18/22
NORTHCOTT JOHN SVP & Chief Commerci.. SVP & Chief Commercial Officer Feb 16 Sell 10.95 4,852 53,129 227,802 02/18/22
Labrucherie Gil M SVP, COO & CFO SVP, COO & CFO Feb 16 Sell 10.95 7,579 82,990 301,603 02/18/22
Labrucherie Gil M SVP, COO & CFO SVP, COO & CFO Aug 18 Sell 13.7 10,867 148,878 240,231 08/18/21
CHESS ROBERT Director Director Apr 16 Option 13.8 8,000 110,400 288,573 04/16/21
CHESS ROBERT Director Director Apr 16 Sell 18.98 8,000 151,840 280,573 04/16/21
Wilson Mark Andrew SVP & General Counse.. SVP & General Counsel Feb 04 Option 8.8 5,344 47,027 84,244 02/04/21
Wilson Mark Andrew SVP & General Counse.. SVP & General Counsel Feb 04 Sell 19.45 5,344 103,941 78,900 02/04/21
ROBIN HOWARD W President & CEO President & CEO Feb 04 Option 8.8 450,000 3,960,000 608,693 02/04/21
ROBIN HOWARD W President & CEO President & CEO Feb 04 Sell 20.42 450,000 9,189,000 458,693 02/04/21
Labrucherie Gil M SVP, COO & CFO SVP, COO & CFO Feb 04 Option 8.8 150,000 1,320,000 316,973 02/04/21
Labrucherie Gil M SVP, COO & CFO SVP, COO & CFO Feb 04 Sell 20.4 150,000 3,060,000 266,973 02/04/21
Thomsen Jillian B. SVP & Chief Accounti.. SVP & Chief Accounting Officer Jan 29 Option 8.8 75,000 660,000 251,257 01/29/21
Thomsen Jillian B. SVP & Chief Accounti.. SVP & Chief Accounting Officer Jan 29 Sell 18.62 75,000 1,396,500 176,257 01/29/21